Rituximab in relapsed or refractory hairy cell leukemia.
about
Hairy cell leukemia: current conceptsSuccessful treatment of hairy cell leukemia variant with rituximab.Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.Update on the biology and treatment options for hairy cell leukemia.Cladribine: from the bench to the bedside--focus on hairy cell leukemia.My treatment approach to hairy cell leukemia.2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.Hairy cell leukemia - immunotargets and therapiesLong-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option.Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.Combination therapies to improve the long-term outcome in hairy cell leukemia.Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.Approach to the patient after relapse of hairy cell leukemia.Hairy cell leukemia: short review, today's recommendations and outlook.Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis.Chemo-immunotherapy for hairy cell leukemia.Infectious complications in hairy cell leukemia.Fifty years of hairy cell leukemia treatments.Hairy cell leukaemia: biological and clinical overview from immunogenetic insights.Hairy cell leukemia-new genes, new targets.Novel therapeutic options for relapsed hairy cell leukemia.Potential breakthroughs with investigational drugs for hairy cell leukemia.How I manage patients with hairy cell leukaemia.Hairy cell leukemia: current therapies and future directions.A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).Rituximab in the treatment of non-Hodgkin's lymphomaLong-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040.Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
P2860
Q28294251-2761301A-BA4B-402C-BF97-E13EAA5E8238Q33367714-594069FA-43D2-42DA-8AD1-8AF66D00084BQ34146996-5A86C55C-81BA-457B-A51D-90E7B073E926Q34343369-37AF546F-7108-4410-815C-2C4214FAC257Q35918435-D4A0C7F3-623F-4F9D-962E-B76C2F7A1FCFQ36399120-94C35297-3B2F-4EE2-B2A4-2C6B00CF6987Q36654614-4CB506A9-0772-4DD1-B723-B5234413027BQ36687989-A7D8B172-C086-4610-87F5-E8E86C750B28Q37031666-7F6812FB-2C3F-4299-B5C7-70733C7E7224Q37043067-DAD06A99-C207-472C-8F03-B1445B8A716AQ37242280-5EF5418D-537E-49B8-A6DE-B15B8EF15529Q37611065-8FA45236-E0F8-4534-97A7-887FE86E05D2Q37611073-46470C11-AFA0-47F5-9226-E30B5E4431B0Q37611077-A51D676D-6C68-4AE5-AC7B-3DC4CDC19612Q37611080-45A32930-2EFE-405E-ABD7-65C3E4D8AF41Q37621357-C59E505A-BD44-4591-AE2B-0C0C33FC3AD1Q37816419-7DE55779-2416-4E8D-A4ED-44F88F40CF4FQ37854692-F754AA08-1727-4ED4-83A2-BAE68D6B4B24Q37866770-4123C0B9-A061-439E-8E97-AF08BDBC3CCFQ37877732-44362B46-AF3C-43E1-8A6A-7FE94AD36F73Q37889776-16788110-46DA-4375-A287-37930748FE3DQ38124726-71FC1EDA-370F-4BFF-93CF-0740E9B5A3AAQ38308974-E247AB3F-5478-4867-9102-5FDCFEA087FFQ38578492-4E2B13DC-3521-4102-B485-199EB1E9B57AQ39113513-776B906B-A39C-463A-873E-C1580E7C1625Q39815355-E52D4AE0-2A2B-466E-B8B4-046EA26415C9Q40343878-F1E16F35-FED6-4D45-9593-86E6116DE4A2Q40382518-DA1CA267-6738-46A3-AD33-555E4CBD01BCQ41925899-EFF43A48-5BAA-485C-8C8B-7C8B7890AE68Q42291047-C081B260-B93E-45C8-BFF5-EF5440045776Q43083993-B1B36338-164F-406C-97EF-FBBA30C71F8DQ44960566-E83DFF53-1311-49B7-9CF9-765FEDEF532DQ46860351-6987EF7A-C8B4-49FD-8CDC-BD47FBE5CF78Q46912367-04817ACE-07DB-4E02-A1C4-2A3AC13E6436Q56355787-41D7D6A3-1499-4D4F-83FD-F193ED41B1D6
P2860
Rituximab in relapsed or refractory hairy cell leukemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rituximab in relapsed or refractory hairy cell leukemia.
@ast
Rituximab in relapsed or refractory hairy cell leukemia.
@en
Rituximab in relapsed or refractory hairy cell leukemia.
@nl
type
label
Rituximab in relapsed or refractory hairy cell leukemia.
@ast
Rituximab in relapsed or refractory hairy cell leukemia.
@en
Rituximab in relapsed or refractory hairy cell leukemia.
@nl
prefLabel
Rituximab in relapsed or refractory hairy cell leukemia.
@ast
Rituximab in relapsed or refractory hairy cell leukemia.
@en
Rituximab in relapsed or refractory hairy cell leukemia.
@nl
P2093
P50
P1433
P1476
Rituximab in relapsed or refractory hairy cell leukemia.
@en
P2093
Carlos Bueso-Ramos
Deborah A Thomas
Francis J Giles
P304
P356
10.1182/BLOOD-2003-02-0630
P407
P577
2003-06-19T00:00:00Z